Table 3.
Treatment modalities in young breast cancer patients (N = 144) and their associations with disease progression (HR hazard ratio, CI confidence interval)
| Treatment modalities | N | % | HR (95%CI) |
|---|---|---|---|
| Surgery | |||
| Palliative | 16 | 11.10% | 2.915 (0.775–10.965) |
| Radical | 121 | 84% | ref |
| Conservative | 7 | 4.90% | |
| Chemotherapy | |||
| Neoadjuvant | 6 | 4.20% | 1.667 (0.310–8.976) |
| Adjuvant | 98 | 68% | |
| Palliative | 23 | 16% | |
| No | 26 | 11.80% | ref |
| Radiotherapy | |||
| No | 29 | 20.10% | 0.836 (0.321–2.1770 |
| Waiting list | 13 | 9% | |
| Yes | 102 | 70.80% | ref |
| Hormonal therapy | |||
| Yes | 49 | 34% | ref |
| No | 8 | 5.60% | 1.04 (0.49–2.207) |
| HR-negative | 86 | 59.700% | |
| Anti-HER2 therapy | |||
| HER2 positive | 44 | 30.60% | |
| No | 26 | 18.10% | 0.844 (0.203–3.504) |
| Yes | 18 | 12.50% | ref |
| Bisphosphonate treatment | |||
| Yes | 17 | 11.80% | N/A |
| No | 6 | 4.20% | N/A |
| Bone metastases | 23 | 16% | |